Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
Authors' conclusion
After tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower 'improved' BMI category. This shift was generally associated with numerical improvements in selected cardiometabolic measures and weight-related PROs that may reduce cardiometabolic risk.
Study context
- Population
- Adults with T2D treated with weekly tirzepatide (pooled doses) in SURPASS-1 to −5; Body mass index (BMI) categories <25, 25 to <30, 30 to <35, 35 to <40 and ≥40 kg/m²
- Participants
- 3,559 adults
- Comparison
- Improved vs not improved BMI category after tirzepatide
- Primary endpoint
- Change in BMI category from baseline
- Follow-up
- Week 40 or 52
Methodological detailspooled tirzepatide doses
- Pooled tirzepatide doses
Primary result
As reported in the abstract
BMI category shift
Further findings
Cardiometabolic parameters · endpoint
- Numerically larger mean improvements from baseline in most selected cardiometabolic parameters with improved vs not improved BMI category, in all five SURPASS trials
Weight-related patient-reported outcomes (PROs)
- Improvements in weight-related PROs numerically largest with improved BMI category
Original publication
Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide. Diabetes Obes Metab. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →